Immuron Limited

Immuron Limited is a Carlton (Melbourne), Australia-based biopharmaceutical company commercializing oral hyperimmune (polyclonal antibody) products for gastrointestinal and infectious-disease indications. Its marketed products are Travelan, an over-the-counter medicine reducing the risk of travelers' diarrhea and minor gastrointestinal disorders, and Protectyn, an immune supplement supporting digestive and liver health; the pipeline extends the platform to IMM-124E (Travelan) in Phase II for travelers' diarrhea, IMM-529 in Phase II for recurrent Clostridium difficile infection, and preclinical IMM-986, with development collaborations with the U.S. Naval Medical Research Command and the Walter Reed Army Institute of Research. On September 4, 2026 the company announced an exclusive U.S. distribution agreement with Calmino Group AB for PROIBS, its irritable-bowel-syndrome digestive-health product, alongside FY2026 results that beat guidance with four consecutive quarters of growth.